Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.

Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW.

Blood. 2010 Oct 28;116(17):3278-85. doi: 10.1182/blood-2008-10-183665. Epub 2010 Jun 2.

2.

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T.

Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.

3.

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.

Donato NJ, Fang D, Sun H, Giannola D, Peterson LF, Talpaz M.

Biochem Pharmacol. 2010 Mar 1;79(5):688-97. doi: 10.1016/j.bcp.2009.10.009. Epub 2009 Oct 27.

PMID:
19874801
4.

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.

Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD.

Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7. doi: 10.1073/pnas.0812413106. Epub 2009 Jan 21.

5.

Activation of tyrosine kinases by mutation of the gatekeeper threonine.

Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ.

Nat Struct Mol Biol. 2008 Oct;15(10):1109-18. doi: 10.1038/nsmb.1486. Epub 2008 Sep 14.

6.

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.

Blood. 2008 Apr 15;111(8):4355-64. doi: 10.1182/blood-2007-09-113175. Epub 2008 Feb 11.

7.

Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.

Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A, Moll J.

Cancer Res. 2007 Sep 1;67(17):7987-90.

8.

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL.

J Clin Invest. 2007 Sep;117(9):2562-9.

9.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators.

N Engl J Med. 2006 Dec 7;355(23):2408-17.

10.

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C.

Cancer Res. 2006 Dec 1;66(23):11314-22. Epub 2006 Nov 17.

11.

Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism.

Kornev AP, Haste NM, Taylor SS, Eyck LF.

Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17783-8. Epub 2006 Nov 9.

12.

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S.

Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5. Epub 2006 Oct 31.

13.

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.

Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ.

Blood. 2007 Jan 15;109(2):500-2. Epub 2006 Sep 21.

14.

Rational design of inhibitors that bind to inactive kinase conformations.

Liu Y, Gray NS.

Nat Chem Biol. 2006 Jul;2(7):358-64.

PMID:
16783341
15.

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG.

N Engl J Med. 2006 Jun 15;354(24):2542-51.

16.

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE.

Cancer Res. 2006 Jun 1;66(11):5790-7.

17.

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD.

Br J Cancer. 2006 Jun 19;94(12):1765-9. Epub 2006 May 23. Review.

18.

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J.

Cancer Res. 2006 Jan 15;66(2):1007-14.

19.

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.

Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Büttner R, Bihl H, Leutner CC, Heinicke T, Hohenberger P.

Lancet Oncol. 2005 Apr;6(4):249-51. No abstract available.

PMID:
15811621
20.

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H.

PLoS Med. 2005 Mar;2(3):e73. Epub 2005 Feb 22.

Supplemental Content

Support Center